C4 Therapeutics (CCCC) Enterprise Value (2019 - 2026)

C4 Therapeutics' Enterprise Value history runs 8 years deep, the most recent figure standing at -$235.7 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 40.92% year-over-year to -$235.7 million in Q1 2026; TTM through Mar 2026 was -$235.7 million, a 40.92% decrease from a year earlier, with the FY2025 full-year figure at -$248.5 million, down 1.48% from the prior year.
• Enterprise Value advanced to -$235.7 million in Q1 2026 per CCCC's latest filing, from -$248.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$130.5 million in Q4 2023 and bottomed at -$307.8 million in Q2 2022.
• The 5-year median for Enterprise Value is -$235.7 million (2026), against an average of -$221.6 million.
• Across the five-year window, Enterprise Value soared 47.72% in 2023 and tumbled 87.62% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$249.7 million in 2022, then soared by 47.72% to -$130.5 million in 2023, then tumbled by 87.62% to -$244.9 million in 2024, then decreased by 1.48% to -$248.5 million in 2025, then advanced by 5.18% to -$235.7 million in 2026.
• Per Business Quant, the three latest CCCC Enterprise Value figures stand at -$235.7 million (Q1 2026), -$248.5 million (Q4 2025), and -$136.5 million (Q3 2025).